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Abstract
Background: Exhaled biomarkers may be related to disease processes in idiopathic pulmonary fibrosis (IPF)
however their clinical role remains unclear. We performed a systematic review to investigate whether breath
biomarkers discriminate between patients with IPF and healthy controls. We also assessed correlation with lung
function, ability to distinguish diagnostic subgroups and change in response to treatment.
Methods: MEDLINE, EMBASE and Web of Science databases were searched. Study selection was limited to adults
with a diagnosis of IPF as per international guidelines.
Results: Of 1014 studies screened, fourteen fulfilled selection criteria and included 257 IPF patients. Twenty
individual biomarkers discriminated between IPF and controls and four showed correlation with lung function.
Meta-analysis of three studies indicated mean (± SD) alveolar nitric oxide (CalvNO) levels were significantly higher in
IPF (8.5 ± 5.5 ppb) than controls (4.4 ± 2.2 ppb). Markers of oxidative stress in exhaled breath condensate, such as
hydrogen peroxide and 8-isoprostane, were also discriminatory. Two breathomic studies have isolated
discriminative compounds using mass spectrometry. There was a lack of studies assessing relevant treatment and
none assessed differences in diagnostic subgroups.
Conclusions: Evidence suggests CalvNO is higher in IPF, although studies were limited by small sample size. Further
breathomic work may identify biomarkers with diagnostic and prognostic potential.
Keywords: Idiopathic pulmonary fibrosis, Breath tests, Nitric oxide, Volatile organic compounds, Exhaled breath
condensate
Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common
form of interstitial lung disease (ILD) with an estimated
incidence of 2.8–9.3 per 100,000 per year in Europe and
North America [1]. It is associated with high morbidity
and mortality with a reported median survival of ap-
proximately three years [2]. Challenges exist, particularly
in relation to diagnosis and clinical phenotyping [3, 4].
Diagnostic criteria for IPF have evolved over time and
have recently been updated [5]. There is risk of misdiag-
nosis, particularly as inter-observer agreement amongst
clinicians is variable [6, 7]. Surgical biopsy rates remain
low due to concerns regarding associated mortality and
morbidity, particularly in an elderly, comorbid patient
group [8]. In addition, it is well recognised that signifi-
cant heterogeneity exists within the IPF population in
relation to disease progression [9, 10]. At present, lung
function parameters remain the most widely used tool to
monitor disease activity in IPF and the most commonly
used end point in therapeutic trials [11]. An absolute an-
nual decline in forced vital capacity (FVC) of 10% or dif-
fusion capacity for carbon monoxide (DLCO) of 15% has
been shown to be an accurate predictor of mortality in
IPF [12–14]. However, baseline FVC measurements do
not have strong prognostic value and limitations exist
with respect to interpretation of longitudinal changes
[15, 16]. Baseline DLCO may be slightly better at predict-
ing mortality in IPF [2], however results may be
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significantly affected by the presence of co-morbidity,
such as pulmonary hypertension and emphysema [17].
Other physiological parameters associated with disease
prognosis include total lung capacity (TLC) and 6-min
walk distance [14, 18]. Composite scoring systems such
as the Composite-Physiologic Index (CPI) and Gender
Age Physiology (GAP) index [19, 20], which incorporate
demographic and physiological data, may represent
more accurate prognostic models.
It is recognised that there is a need for additional bio-
markers to augment the diagnostic process, facilitate clin-
ical phenotyping, improve accurate disease monitoring
and identify potential therapeutic targets in IPF [21, 22].
Several serological markers, including Krebs von den
Lungen-6 (KL-6), Surfactant protein-A (SP-A) and D
(SP-D), and matrix metalloproteinase-7 (MMP-7) have
been identified as having potential diagnostic and prognos-
tic value [23–28], while the PROFILE (Prospective Obser-
vation of Fibrosis in the Lung Clinical Endpoints) study, an
ongoing prospective multicentre study aimed at biomarker
discovery, has identified further novel serological protein
markers with prognostic potential [29, 30].
Exhaled breath may represent an alternative source of
novel biomarkers in IPF. There has been an interest in
breath research in respiratory disease for many years [31].
In asthma, exhaled nitric oxide (NO) has successfully
transitioned from research to clinical practice and its use
is now recommended in international clinical guidelines
for diagnosis and monitoring [32–35]. Fractionated ex-
haled nitric oxide measured at a flow rate of 50ml/s
(FeNO50) using either a chemiluminescence, electrochem-
ical or laser analyser is used as a surrogate marker of in-
flammation in the airways [33]. Capturing FeNO at
different flow rates also allows estimation of the concen-
tration of NO at the level of the alveolus (CalvNO) and air-
way wall (CawNO), as well as diffusion capacity (DawNO)
and airway flux (JawNO) [36, 37]. An alternative medium
for breath sampling is exhaled breath condensate (EBC),
which is comprised of condensed water vapour with small
amounts of non-volatile and water-soluble volatile mole-
cules within [38, 39]. Following collection, relevant ana-
lytes can be measured using specific assays or mass
spectrometry [39]. More recently, interest in volatile or-
ganic compounds (VOCs) as a potential source of bio-
markers in respiratory disease has been gathering pace
[40–43]. In particular high-throughput “breathomics”
using gas chromatography-mass spectrometry (GC-MS),
may allow discovery of novel volatile compounds with
highly specific diagnostic, therapeutic or prognostic po-
tential [40, 42]. These methods have been used to identify
VOCs in a number of respiratory diseases including
asthma [44], COPD [45], pneumonia [46] and lung cancer
[47]. Electronic noses (“E-noses”), sensors which detect
specific patterns of VOCs, have also been tested in a
number of respiratory conditions and may represent a
more clinically accessible diagnostic tool [48]. Figure 1 de-
tails the breadth of current approaches for breath analysis.
Breath sampling represents an attractive investiga-
tive method, being both non-invasive, simple to col-
lect and unlimited in quantity. However, the utility of
breath analysis in IPF is unclear. The aim of this
systematic review was to investigate the role of breath
biomarkers in IPF. The primary aim was to establish
which breath biomarkers are significantly different in
the IPF population compared to healthy controls. We
also hoped to answer whether biomarkers correlate
with lung function parameters within the IPF
population, differ between treated and untreated
patients and between patients with and without
honeycombing.
Materials and methods
We performed this systematic review using PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines [49]. The review was registered
with the International prospective register of systematic re-
views (PROSPERO) (Registration ID CRD42017078645).
Search strategy and study selection
Two reviewers performed independent electronic data-
base searches in January 2018. Databases searched were
MEDLINE (using both PubMed and Ovid), EMBASE
and Web of Science. Searches were performed using a
combination of MeSH and key word terms. The search
terms used were (idiopathic pulmonary fibrosis OR pul-
monary fibrosis OR lung diseases, interstitial OR fibros-
ing alveolitis OR diffuse parenchymal lung disease OR
usual interstitial pneumonia) AND (breath tests OR
volatile organic compounds OR metabolomics OR
breath analysis OR breath biomarkers OR breathomics
OR exhaled breath).
Study selection was performed based on the following
eligibility criteria. Inclusion criteria were: age over 18; a
diagnosis of idiopathic pulmonary fibrosis based on
international guidelines[2, 50]; primary research involv-
ing breath biomarkers; comparison control group of
healthy participants or comparison within IPF popula-
tion based on lung function or treatment strategy. Ex-
clusion criteria were: non-human studies; review
articles; research in abstract form only; non-english lan-
guage publications. Each reviewer performed abstract
and full text review to identify studies which met selec-
tion criteria. Reference lists of retrieved articles were
reviewed to identify additional papers. Google Scholar
(https://scholar.google.co.uk) was used to identify any
additional articles which may have cited the retrieved
articles.
Hayton et al. Respiratory Research            (2019) 20:7 Page 2 of 16
Data extraction and quality assessment
Data extraction and quality assessment of all the selected
studies was performed independently by both reviewers.
Quality was assessed using the QUADAS-2 tool [51].
This facilitates the assessment of studies of diagnostic
tests for bias and applicability in four domains; patient
selection, index test, reference test and flow and timing.
In this review, the index test was the biomarker under
investigation and the reference test was a diagnosis of
IPF based on international guidelines [2, 50].
Data extraction was performed using an electronic
data collection form. Data collected included country
and year of publication, method of breath collection and
analytical technique, number of IPF and control patients,
baseline characteristics (e.g. age, gender, smoking status)
and significant differences between groups, treatment
regimens, reported lung function parameters, biomarker
levels and reported differences between groups.
All studies identified were included in qualitative data
synthesis. Quantitative data synthesis was performed
where three or more studies reported the same outcome.
This consisted of random effects meta-analysis of mean
difference in biomarker levels (IPF vs controls) with I2
statistic to assess heterogeneity. Reported mean and
standard deviation (SD) of biomarker levels were in-
cluded in the analysis. If studies reported standard error
(SE), this was converted to SD. Statistical analysis was
performed using OpenMeta-Analyst software [52].
Results
Following removal of duplicates, we identified 1014 arti-
cles through databases searches, reference lists and
citing articles. The results for each database searched
can found in Additional file 1. Title and abstract screen-
ing identified 53 articles for full text review of which 39
did not fulfil selection criteria for data analysis (See
Additional file 2 for details). Fourteen studies were
included in qualitative data synthesis and three were in-
cluded in quantitative data synthesis. Figure 2 summa-
rises the search results.
The 14 studies included a total of 257 patients with idio-
pathic pulmonary fibrosis. There was significant hetero-
geneity within the included studies in terms of study
design, breath analysis technique and biomarkers investi-
gated. Sixty-seven targeted biomarkers were measured
with additional non-targeted metabolomic studies. Table 1
summarises the results of the included studies with refer-
ence to the primary and secondary research questions.
None of the studies included in this review made com-
parison between IPF patients with evidence of honey-
combing and those without documented honeycombing.
Study quality and risk of bias
Figure 3 summarises the risk of bias and applicability
concern across the domains of the QUADAS-2 tool. The
quality assessment for each study using the QUADAS-2
tool is presented in Additional file 3. In general, there
were significant issues with bias particularly concerning
patient selection. The majority of the studies were of a
case-control design, however controls were frequently
not matched for age and smoking status, both of which
have been shown to influence results of breath analysis
[53]. Sample sizes were small across the spectrum of
studies included with the number of IPF patients
Fig. 1 The spectrum of breath analysis. Exhaled breath contains a vast quantity of molecules and particles, ranging in size and volatility, which
can be captured using analytical techniques. Nitric oxide is a very small, volatile compound which can be detected using an online analyser
which will provide an instant measurement of the concentration in exhaled breath (a). Large, non-volatile particles can be detected in exhaled
breath condensate, either through liquid chromatography-mass spectrometry (b) or enzyme immunoassay (c). Volatile organic compounds (VOCs)
of varying size can be detected by using various technologies including electronic noses (d) or gas-chromatography mass spectrometry (e)
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ranging from 6 to 40. No power calculations were re-
ported in any of the studies. Tests of breath biomarkers
are prone to contamination from several sources includ-
ing environmental, nasal and oral [53]. There was wide
variation on how these were controlled, and the degree
of methodological detail provided. There was also vari-
ation in the analytical equipment and/or assays used,
which has also been shown to influence results and
makes comparison between studies more difficult [39,
53, 54].
Qualitative data synthesis
Which breath biomarkers are significantly different in the
IPF population compared to healthy controls?
Twelve studies compared breath biomarkers in IPF com-
pared to healthy controls. Twenty biomarkers were
found to discriminate between IPF patients and healthy
controls. These are listed in Table 2.
Exhaled nitric oxide was measured in three studies;
[55–57] two studies reported both FeNO50 and CalvNO
[55, 57], and a third reported solely CalvNO. [56] Furu-
kawa et al [55] found no difference in FeNO50 levels in
IPF patients compared to controls, although the two
groups were not well matched for gender or smoking
history. Cameli et al [57] found that FeNO levels were
higher in patients with IPF at flow rates of 50 ml/s as
well as 100 ml/s (FeNO100) and 150 ml/s (FeNO150).
These two studies, along with a study by Zhao et al, [56]
also reported CalvNO in patients with IPF and healthy
controls (see quantitative data synthesis).
Eight studies measured biomarkers present in EBC in
patients with IPF and healthy controls [55, 58–64].
These included markers of oxidative stress [8-isopros-
tane, hydrogen peroxide (H202), malondialdehyde
(MDA)], markers of nitrosative stress (nitrite and ni-
trate), metallic elements, and cytokines. Two studies
Fig. 2 Summary of study selection process based on PRISMA flow diagram [49]
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found significantly higher levels of 8-isoprostone in IPF
patients (25-74 pg/mL) compared to controls (5-33 pg/
mL) [58, 62]. One study investigated lysophosphatidic
acid (LPA) species in EBC from 11 IPF patients and 11
healthy controls using liquid chromatography-tandem
mass spectrometry to identify the presence of total LPA
and subspecies of LPA [63]. There was no difference in
total LPA levels between the two groups but one species,
docosatetraenoyl (22:4) LPA, was significantly higher in
IPF compared to controls. These results may have been
skewed by an outlier patient with extremely high levels
of 22:4 LPA. This patient was subsequently hospitalised
and treated for an exacerbation of IPF within ten days of
collection and received urgent lung transplantation. There
were no data presented that excluded this patient. Rindlis-
bacher et al [64] analysed EBC samples from ten patients
with a diagnosis of IPF and ten age-matched controls
using ultra high-performance liquid chromatography
coupled to high-resolution mass spectrometry to identify
discriminative metabolites using a non-targeted approach.
A validation set of samples was taken from eight of the
IPF patients and eight additional controls. The initial ana-
lysis identified 58 metabolic features which were signifi-
cantly different between the IPF group and the healthy
controls with 48 being identified in the validation set.
Only two discriminative features were found to be present
in both the pilot and the validation sets and of these only
one was regulated in the same direction in both sets. This
discriminative feature was two-fold up-regulated in IPF
compared to healthy controls. They speculated that the
potential molecular formula was C21H44N2O but were un-
able to identify a metabolite from known databases.
Two studies assessed VOCs in IPF patients and
healthy controls [65, 66]. Yamada et al [66] examined
VOCs in breath samples of 40 patients with IPF and 55
healthy controls. Samples were analysed using
a
b
Fig. 3 Proportion of studies included with high, low or unclear risk of bias (a) and applicability concerns (b) as per QUADAS-2 tool
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multicapillary column ion mobility spectrometry.
Through this method they identified 85 VOC peaks in
IPF patients and healthy controls, with significant differ-
ences in five. They identified these as p-cymene, acetoin,
isoprene, ethylbenzene and an unidentified compound
(peak 67). P-cymene was found to be lower in patients
with IPF while the other compounds were higher in IPF.
Isoprene was found to carry the highest diagnostic ac-
curacy. This study was limited by the age difference be-
tween the two groups (IPF mean age 70, control mean
age 38) and gender differences with a higher proportion
of females in the control group. Another study assessed
the ability of a colorimetric sensor to detect patterns of
VOCs in lung cancer patients [65]. They also included
patients with IPF and healthy controls in the cohort.
Sensitivity of 40% and specificity of 93% for IPF was re-
ported although this was not validated. Diagnosis was
confirmed either clinically or histologically, however
international guidelines were not referenced.
Do levels of breath biomarkers in the IPF population
correlate with lung function parameters?
Six studies assessed correlation between breath bio-
markers and lung function in IPF patients [58, 59, 63,
66–68]. Kotecha et al [68] compared CalvNO levels in 27
IPF patients whose lung function had been declining in
the previous 6–12 months to those with stable lung
function. CalvNO levels were noted to be significantly
higher in the 16 patients with declining lung function.
Psathakis et al [58] found a negative correlation with
DLCO % predicted with both H202 and 8-isoprostane al-
though no association was noted with other measures of
pulmonary function. Yamada et al [66] found that
P-cymene had a negative correlation with lung function
parameters including FVC and DLCO. Ethylbenzene had
a negative correlation with %DLCO/VA (diffusion cap-
acity per litre lung volume). No correlation was noted
with levels of cysteinyl leukotrienes (CysLTs), Docosate-
traenoyl (22:4) LPA or metallic elements in EBC and
lung function parameters in IPF [59, 63, 67].
Do levels of breath biomarkers in the IPF population differ
between treated and untreated patients?
Two studies compared breath biomarkers in IPF pa-
tients receiving treatment. Kotecha et al [68], found
no difference in CalvNO levels in IPF patients receiv-
ing treatment with immunosuppression (either corti-
costeroids alone or in combination with azathioprine)
and untreated patients. Corradi et al [59] found that
there was no treatment effect on the presence of
Table 2 Biomarkers reported to discriminate between IPF patients and healthy controls. Direction of discrimination and reported
p-value. aCalvNO.
bFeNO50/FeNO100/FeNO150/CalvNO
Biomarker Sample Medium Discrimination p-value References
Nitric Oxide Exhaled breath Higher in IPF 0.0001, < 0.0001 [62]a, [65]b
8-isoprostane EBC Higher in IPF 0.02, < 0.05 [58], [62]
Hydrogen Peroxide EBC Higher in IPF 0.003 [58]
Nickel EBC Higher in IPF < 0.05 [59]
Chromium EBC Higher in IPF < 0.05
Silicon EBC Higher in IPF < 0.05
Cobalt EBC Lower in IPF < 0.05
Iron EBC Lower in IPF < 0.05
Copper EBC Lower in IPF < 0.05
Selenium EBC Lower in IPF < 0.05
Molybdenum EBC Lower in IPF < 0.05
Nitrite EBC Higher in IPF < 0.01 [60]
Nitrate EBC Lower in IPF < 0.01
22:4 LPA EBC Higher in IPF 0.001 [63]
Unidentifiable metabolite EBC Higher in IPF ≤0.01 [64]
p-cymene Exhaled breath Lower in IPF < 0.001 [66]
Acetoin Exhaled breath Higher in IPF < 0.001
Isoprene Exhaled breath Higher in IPF < 0.001
Ethylbenzene Exhaled breath Higher in IPF < 0.001
Unidentified VOC Exhaled breath Higher in IPF < 0.001
IPF idiopathic pulmonary fibrosis, EBC exhaled breath condensate, 22:4 LPA Docosatetraenoyl lypophosphatidic acid, VOC volatile organic compound, CalvNO
alveolar nitric oxide concentration, FeNO50/100/150 fractionated exhaled nitric oxide at 50ml/100 ml/150 ml per second
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metallic elements in EBC of IPF patients. Treatment
regimens included steroids, immunosuppression and
pirfenidone, although this group of patients included
both IPF and non-specific interstitial pneumonia
(NSIP) diagnoses, and only two patients were receiv-
ing pirfenidone.
Quantitative data synthesis
Three studies compared CalvNO levels in IPF patients
and controls and were included in meta-analysis [55–
57]. Each study reported CalvNO using both the Tsoukias
and George method [36] and corrected for axial diffu-
sion using the Condorelli method [69]. The range of
values reported for CalvNO using the Tsoukias and
George method was 4.4–11.8 ppb for IPF patients and
2.9–5.1 ppb for healthy controls. Using the Condorelli
method the range was 3.9–10. 7 ppb for IPF patients and
1.7–4.5 ppb for healthy controls. We performed
meta-analysis to compare mean difference in CalvNO
(ppb) levels between IPF patients and healthy controls,
using both Tsoukias and George and Condorelli
methods. Figure 4 shows the forest plots. Meta-analysis
suggested that CalvNO was significantly higher in pa-
tients with IPF using either method, however the total
number of patients included was small (n = 101) and sig-
nificant heterogeneity between the studies was noted
(I2 = 83% & 84%, p = 0.002).
Discussion
This systematic review has highlighted the heterogeneity
of results from breath research in IPF. Over 60 known
biomarkers and multiple unknown molecules have been
investigated within a total patient cohort of less than
300 patients using a wide variety of analytical tech-
niques. In this context, it is difficult to draw any firm
conclusions regarding potentially clinically relevant
markers. Twenty individual biomarkers were reported to
discriminate between IPF and healthy controls however
most of the studies did not include a validation cohort
and there was an absence of longitudinal data. Only two
of these biomarkers, exhaled NO and 8-isoprostane,
have been studied more than once.
Exhaled NO is a breath biomarker which is easily
measurable and already used in asthma care [32–35].
NO is a free radical that is implicated in a wide variety
of physiological and pathophysiological processes [70]. It
has been suggested that NO may increase the expression
of pro-fibrotic mediators, such as transforming growth
factor-β (TGF-β1), in lung fibrosis [71]. Two studies re-
ported that measurements of exhaled nitric oxide were
elevated in IPF compared to healthy controls [56, 57].
This is supported by an additional study which found
that exhaled NO levels measured at a non-specific flow
rate between 5 and 6 L/min were significantly higher in
patients with a diagnosis of cryptogenic fibrosing alveol-
itis (CFA) compared to healthy non-smoking controls
Fig. 4 Random effects meta-analysis of mean difference in CalvNO (ppb) between groups (IPF vs Healthy controls) using Tsoukias and George (a)
and Condorelli (b) methods of calculation
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[72]. This study was excluded from this systematic re-
view as it preceded international standards for IPF diag-
nosis. In clinical practice FeNO50 is the most common
method used for measuring and reporting NO in breath.
NO measured at this flow rate contains a higher propor-
tion of airway and lower proportion of alveolar NO [54].
FeNO50 did not show consistency in IPF, [55, 57] or
other forms of interstitial lung disease [73, 74]. FeNO50
levels in IPF patients ranged from 20.8–31.5 ppb [55, 57,
67]. It has been reported that the upper limit of FeNO50
in healthy adults ranges from 30.3–50.6 ppb depending
on age and gender [75].
Although, FeNO50 is unlikely to be of use in IPF,
CalvNO may have potential as a clinical biomarker.
Meta-analysis in this review, while limited by small sam-
ple size and significant heterogeneity, suggests that
CalvNO is higher in IPF patients compared to controls.
Average CalvNO levels for patients with IPF were 8.5
(±5.5) ppb compared to 4.4 (±2.2) ppb for healthy con-
trols. In a recent study of 433 healthy individuals, the
upper limit of CalvNO reported was 3.88-3.93, depending
on age [76]. Elevated alveolar NO supports a patho-
physiological role in lung fibrosis. Nitrite, another medi-
ator of nitrosative stress was also elevated in pulmonary
fibrosis [60, 77]. CalvNO, but not FeNO, has also been
reported to be elevated in ILD related to systemic scler-
osis [78–80]. Increased exhaled NO levels have been de-
scribed in other forms of ILD including hypersensitivity
pneumonitis (HP), asbestosis and connective tissue dis-
ease related ILD (CTD-ILD), limiting the potential of
the test as a discriminative diagnostic tool [73, 74, 81–
85]. An alternative role for CalvNO may be in disease
monitoring. Kotecha et al [68] suggested that CalvNO
levels were reflective of deteriorating lung function. This
is consistent with other studies suggesting that CalvNO
levels are inversely related to lung function parameters
in fibrotic ILD, a phenomenon not seen with FeNO [73,
81, 83]. However, a paucity of longitudinal data makes it
difficult to draw any firm conclusions. Likewise, there is
insufficient evidence to suggest a use for NO in monitor-
ing treatment response in IPF. Only one study reported
on treatment effect and found no difference in CalvNO
levels between patients treated with immunosuppressive
therapy and untreated patients [68]. Lower levels of ex-
haled NO were noted in patients with CFA receiving
treatment with oral corticosteroids [72]. In both studies
patients were receiving either steroid monotherapy or
combination with azathioprine, a treatment regimen
which has since been shown to have negative outcomes
in IPF and is no longer recommended [86]. No studies
have examined exhaled NO levels in patients taking anti-
fibrotic therapy, the treatment of choice for IPF.
Several studies investigated biomarkers in EBC impli-
cated in the pathogenesis of IPF [55, 58–64, 67].
Oxidative stress is one potential mechanism suggested
in the fibrotic process [87]. In vivo, a variety of markers
have been used as a surrogate index of oxidative stress
[31]. A recent systematic review published in Respiratory
Research has identified all the relevant markers of oxida-
tive stress investigated in IPF [88]. These include H202, a
reactive oxygen species, and 8-isoprostane, a
prostaglandin-like compound formed by lipid peroxida-
tion. Both were found to be elevated in EBC in patients
with IPF [58, 62]. 8-isoprostane has also been reported
to be elevated in other forms of fibrotic ILD. [82, 89]
MDA, another marker of lipid peroxidation, was not ele-
vated in EBC of IPF patients compared the healthy con-
trols [61]. However, the authors speculated that this may
have been reflective of a treatment effect as the majority
of the IPF patients were receiving either oral corticoste-
roids or N-acetylcysteine. Additional markers of oxida-
tive stress such as ethane have been reported to be
higher in exhaled breath of patients with IPF and other
forms of ILD [90].
Another study reported differences in concentration of
metallic elements in EBC of patients with IPF compared
to controls [59]. Metal workers are overrepresented in
the IPF population and there is speculation that metal
dust may be implicated in the disease process [91, 92].
The authors identified that nickel, chromium and silicon
were present in higher concentrations in IPF patients
and cobalt, iron, copper, selenium and molybdenum
were higher in controls. This is inconsistent with a pre-
viously reported study using bronchoalveolar lavage fluid
(BALF) which showed lower levels of chromium in IPF
compared to controls and higher levels of iron [93].
Cytokines, such as tumour necrosis factor-α (TNF-α)
and TGF-β, have been strongly implicated in cell signal-
ling in IPF [94, 95]. However no significant differences
were noted in levels of 42 cytokines in EBC of patients
with IPF compared to controls [55]. LPA, a bioactive
lysophospholipid which is believed to have a role in
fibroblast migration, has been shown to be elevated in
BALF of IPF patients [96]. One study did identify ele-
vated levels of 22:4 LPA, a single subspecies of LPA, in
IPF EBC [63], however total LPA levels were not signifi-
cantly different. A recent phase II trial of a selective in-
hibitor of autotaxin (GLPG1690), a key enzyme in the
production of LPA, produced promising safety and effi-
cacy results as well as targeted reduction in plasma con-
centrations of another subspecies of LPA, C18:2 [97]. In
the breath study, mean EBC levels of 18:2 LPA were
higher IPF patients compared to controls, although not
significantly [63], however studies are warranted to as-
sess potential as a prognostic and therapeutic biomarker.
The evidence for EBC biomarkers in IPF is limited.
These were primarily exploratory studies involving small
cohorts and apart from 8-isoprostane, have not been
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reproduced. Currently a biomarker with diagnostic po-
tential has not been identified. There is no evidence that
EBC biomarkers distinguish between IPF and other
forms of fibrotic ILD. Likewise, evidence is limited re-
garding their value as a prognostic marker. Levels of
8-isoprostane and H2O2 did appear to have a negative
correlation with DLCO % predicted in IPF but no rela-
tionship with other lung function parameters [58]. An-
other study suggested no correlation between in EBC
H2O2 and lung function in 21 patients with mixed ILD
including eight patients with IPF [98]. EBC is an appeal-
ing method of breath analysis, particularly as a liquid
sample is obtained allowing a variety of analytical
methods to be performed including specific assays,
metabolomic and proteomic techniques. One possible
disadvantage to EBC measurement in interstitial lung
diseases, is that the technique predominantly samples
respiratory lining fluid and may not accurately reflect a
disease process in the lung interstitium. 8-isoprostane
and H2O2 have both been reported to be elevated in air-
ways disease [99–103], while MDA was shown to be
higher in patients with asthma, COPD and bronchiec-
tasis compared to controls [61]. H2O2 levels have been
reported to be lower in patients with mixed ILD com-
pared to obstructive lung disease [104]. Identification of
molecules with a high specificity for interstitial fibrosis
may be challenging using EBC as they are likely to be
present in extremely small concentrations. One metabo-
lomic study in EBC identified a novel metabolite which
could consistently discriminate between IPF and healthy
controls [64]. Unfortunately in this small pilot study, the
metabolite could not be identified but this work shows
promise and suggests that further work in this field is
warranted.
VOCs offer a promising alternative source of breath
biomarkers in IPF. The advantage of breath volatiles is
that they could potentially travel from the blood or in-
terstitium unaltered before detection in exhaled breath
and therefore contain metabolites with high specificity
for the fibrotic process. VOC work has been limited in
IPF to date. Yamada et al [66] undertook a breathomic
study using multicapillary column ion mobility spec-
trometry. They identified five compounds which could
discriminate between IPF and healthy controls to varying
degrees of accuracy. Isoprene carried the highest diag-
nostic accuracy with an area under the receiver operative
characteristic curve (AUROC) of 0.81. Isoprene is a
by-product of normal cholesterol synthesis and elevated
levels have been noted a variety of disease states [105,
106], and therefore may be of limited use as a specific
biomarker in IPF. Interestingly, lower levels of exhaled
isoprene have been reported in advanced fibrosis of the
liver [107]. P-cymene, which demonstrated an AUROC
of 0.80, may show the most promise as a clinical
biomarker as it displayed the strongest correlation with
markers of disease severity. P-cymene is thought to have
anti-oxidant properties and its reduction in IPF may cor-
relate with the putative theory of increased oxidative
stress [108]. This was the largest of the included studies
with 95 subjects recruited. Despite this there were issues
with case-control matching as the control group were
significantly younger than the IPF group and were also
not matched for gender and smoking history. However,
this study highlights the potential for breathomic discov-
ery of novel biomarker with both diagnostic and prog-
nostic potential. Once specific biomarkers or patterns of
biomarkers (“breathprints”) have been identified, tailored
diagnostic tools such as electronic noses which are more
accessible in the clinical setting, could be developed.
“E-noses” capable of detecting VOCs have been success-
fully used to phenotype and monitor treatment response
in a number of conditions including COPD and ob-
structive sleep apnoea [109–111].
The process of biomarker development is often de-
scribed as the “biomarker pipeline” and thus far none of
the potential candidates have progressed past the bio-
marker discovery phase [112]. It can take decades to
translate from the discovery phase to a clinically vali-
dated biomarker and the results of this systematic review
likely reflect the fact that biomarker development in IPF
remains in its infancy. Studies of blood biomarkers in
IPF, in which there has been a larger body of work, have
thus far failed to identify a candidate with sufficient
diagnostic or prognostic accuracy [5, 113]. The patho-
physiology of IPF is complex and our understanding of the
multiple processes and pathways is evolving [114]. This is a
double edged sword as multiple potential biomarker candi-
dates may exist, but identifying an individual marker which
independently correlates with disease activity is extremely
challenging. Likewise, development of biomarkers in IPF is
particularly difficult due to lack of a gold standard diagnos-
tic test. Diagnosis is made on consensus from a combin-
ation of available information, predominantly radiological,
and it is not uncommon for this to be a “working diagnosis”
[115, 116]. Uncertainty of the accuracy of the reference
standard inherently limits the reliability of the potential bio-
marker. It would be unfeasible to perform a biomarker
study solely in patients with biopsy proven disease, as these
are performed infrequently and generally in a younger,
non-representative cohort [8]. VOCs have been measured
in the “headspace” of in-vitro models of disease, for ex-
ample lung cancer cell lines [117], however it is difficult to
replicate IPF in cellular models [118].
The hope is that biomarker discovery studies inform
our understanding of the pathophysiology of IPF and im-
prove accuracy of diagnosis. In addition, novel bio-
markers may be able distinguish some of the phenotypes
that appear to exist within IPF [10]. Progress is certainly
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required if a clinically relevant breath biomarker is to
emerge in IPF. Further breathomics studies are war-
ranted. Longitudinal studies would be beneficial as this
would increase the data pool considerably and allow in-
dividual reproducibility to be assessed. It would also pro-
vide the opportunity to better evaluate the impact of
initiating treatment on biomarker levels, an issue which
may confound cross-sectional studies.
Limitations
There are several limitations to this systematic review.
We defined IPF based on international consensus
guidelines [2, 50]. This necessitated excluding studies
involving patients that did not meet these diagnostic
standards. One of these studies included patients with
a diagnosis of CFA, pre-dating diagnostic guidelines
[72]. This may have included patients with IPF, but
also those which would now be classified as NSIP.
Several other studies included patients with IPF as a
composite with other forms of fibrotic ILD such as
NSIP, [83] CTD-ILD, [82] or HP [81]. Two studies
measured breath biomarkers in IPF but made com-
parison with other forms of ILD rather than healthy
controls [73, 90]. This was outside the remit of this
systematic review. We excluded studies that were not
published in English. The search strategy identified
two studies, one published in German and one in
Polish, which otherwise met criteria for full text re-
view [119, 120]. We excluded studies presented in ab-
stract form as insufficient detail was provided to
allow accurate and comprehensive data extraction and
quality assessment. These included some studies
which appeared to otherwise fulfil inclusion criteria
(see Additional file 2 for details).
Conclusions
In this PRISMA-compliant systematic review we iden-
tified a heterogeneous group of studies investigating a
wide variety of breath biomarkers in IPF using a
range of analytical techniques. Evidence for the use of
specific biomarkers was inconclusive. Twenty individ-
ual biomarkers were reported to discriminate between
IPF and healthy controls. Meta-analysis of three stud-
ies indicated that CalvNO levels are significantly
higher in patients with IPF compared to healthy con-
trols. CalvNO, 8-isoprostone, hydrogen peroxide and
p-cymene demonstrated correlation with lung func-
tion parameters in IPF patients. There was a lack of
studies investigating relevant treatment options in
IPF. None of the studies compared breath biomarkers
in patients with IPF in relation to the presence of
honeycombing. Recent studies have indicated that a
“breathomic” approach may identify biomarkers with
specificity for IPF [64, 66]. This may be of significant
clinical benefit as diagnosis may be challenging due
to difficulties distinguishing between IPF and other fi-
brotic lung diseases, particularly as a large proportion
of patients are not suitable for surgical lung biopsy.
Larger studies with longitudinal data are required to
identify biomarkers with diagnostic and prognostic
potential.
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